|Dr. Anish Bhatnagar||Pres, CEO, COO & Director||552.25k||N/A||1970|
|Mr. James H. MacKaness||CFO, Principal Financial & Accounting Officer||N/A||N/A||1964|
|Mr. Anthony Wondka||Sr. VP & GM||N/A||N/A||1962|
|Dr. Neil M. Cowen M.B.A., Ph.D., MBA||Sr. VP of Drug Devel.||N/A||N/A||N/A|
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Soleno Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2021 is 9. The pillar scores are Audit: 10; Board: 8; Shareholder Rights: 7; Compensation: 9.